在癌症患者中，加强针在增强对 COVID-19 疫苗的免疫应答方面的效果。
Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer.
机构信息
Department of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Department of Pathology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY 10461, USA.
出版信息
Cancer Cell. 2022 Jan 10;40(1):3-5. doi: 10.1016/j.ccell.2021.11.006. Epub 2021 Nov 16.
Abstract
Anti-COVID-19 immunity dynamics were assessed in patients with cancer in a prospective clinical trial. Waning of immunity was detected 4-6 months post-vaccination with significant increases in anti-spike IgG titers after booster dosing, and 56% of seronegative patients seroconverted post-booster vaccination. Prior anti-CD20/BTK inhibitor therapy was associated with reduced vaccine efficacy.
摘要
在一项前瞻性临床试验中，研究人员评估了癌症患者的抗 COVID-19 免疫动力学。接种疫苗后 4-6 个月，免疫逐渐减弱，但加强针后抗尖峰 IgG 滴度显著升高，56%的血清阴性患者在加强针后转为阳性。既往抗 CD20/BTK 抑制剂治疗与疫苗疗效降低有关。
相似文献
1
Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer.在癌症患者中，加强针在增强对 COVID-19 疫苗的免疫应答方面的效果。
Cancer Cell. 2022 Jan 10;40(1):3-5. doi: 10.1016/j.ccell.2021.11.006. Epub 2021 Nov 16.
2
Immunogenicity of COVID-19 booster vaccination in IEI patients and their one year clinical follow-up after start of the COVID-19 vaccination program.新型冠状病毒肺炎疫苗接种计划启动后，免疫缺陷病（IEI）患者接种新型冠状病毒肺炎加强针的免疫原性及其一年临床随访
Front Immunol. 2024 Apr 18;15:1390022. doi: 10.3389/fimmu.2024.1390022. eCollection 2024.
3
Immunogenicity of Two Doses of BNT162b2 mRNA COVID-19 Vaccine with a ChAdOx1-S Booster Dose among Navy Personnel in Mexico.墨西哥海军人员中两剂BNT162b2 mRNA新冠疫苗加一剂ChAdOx1-S加强针的免疫原性
Viruses. 2024 Apr 1;16(4):551. doi: 10.3390/v16040551.
4
Seroconversion rates following COVID-19 vaccination among patients with cancer.癌症患者接种 COVID-19 疫苗后的血清转化率。
Cancer Cell. 2021 Aug 9;39(8):1081-1090.e2. doi: 10.1016/j.ccell.2021.06.002. Epub 2021 Jun 5.
5
Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.一种雾化型腺病毒 5 型载体新冠疫苗（Ad5-nCoV）在成年人中的安全性、耐受性和免疫原性：一项开放标签、随机 1 期临床试验的初步报告。
Lancet Infect Dis. 2021 Dec;21(12):1654-1664. doi: 10.1016/S1473-3099(21)00396-0. Epub 2021 Jul 26.
6
Immune response against the SARS-CoV-2 spike protein in cancer patients after COVID-19 vaccination during the Omicron wave: a prospective study.奥密克戎变异株流行期间，癌症患者接种 COVID-19 疫苗后针对 SARS-CoV-2 刺突蛋白的免疫应答：一项前瞻性研究。
J Infect Public Health. 2024 Jul;17(7):102473. doi: 10.1016/j.jiph.2024.102473. Epub 2024 Jun 7.
7
Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months.维持性透析患者接种 SARS-CoV-2 疫苗后 6 个月的血清学反应。
Clin J Am Soc Nephrol. 2022 Mar;17(3):403-413. doi: 10.2215/CJN.12250921. Epub 2022 Feb 10.
8
Follow-Up and Comparative Assessment of SARS-CoV-2 IgA, IgG, Neutralizing, and Total Antibody Responses After BNT162b2 or mRNA-1273 Heterologous Booster Vaccination.BNT162b2 或 mRNA-1273 异源加强接种后 SARS-CoV-2 IgA、IgG、中和和总抗体反应的随访和比较评估。
Influenza Other Respir Viruses. 2024 May;18(5):e13290. doi: 10.1111/irv.13290.
9
Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article.癌症患者接种第三剂抗 SARS-CoV-2 疫苗：是否需要监测体液免疫应答？一篇立场文章。
Eur J Cancer. 2022 Feb;162:182-193. doi: 10.1016/j.ejca.2021.12.011. Epub 2021 Dec 16.
10
Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer.癌症患者在接种完初始系列疫苗和加强针 SARS-CoV-2 疫苗后对 SARS-CoV-2 病毒变异株的中和广度。
Cancer Cell. 2022 Jan 10;40(1):103-108.e2. doi: 10.1016/j.ccell.2021.12.002. Epub 2022 Jan 5.
引用本文的文献
1
COVID-19 Vaccination in Patients with Hematological Malignances.血液系统恶性肿瘤患者的新冠病毒疫苗接种
Vaccines (Basel). 2025 Apr 25;13(5):465. doi: 10.3390/vaccines13050465.
2
Delayed but successful development of immune memory against SARS-COV-2 after B cell-depleting monotherapy.在B细胞清除单克隆治疗后，针对SARS-CoV-2的免疫记忆出现延迟但成功发展。
Infection. 2025 May 7. doi: 10.1007/s15010-025-02544-6.
3
Effect of aberrant fructose metabolism following SARS-CoV-2 infection on colorectal cancer patients' poor prognosis.新冠病毒感染后异常果糖代谢对结直肠癌患者预后不良的影响。
PLoS Comput Biol. 2024 Sep 27;20(9):e1012412. doi: 10.1371/journal.pcbi.1012412. eCollection 2024 Sep.
4
Factors Influencing the Intention of Chinese Adults to Recommend COVID-19 Vaccination for Specific or Non-Specific Groups.影响中国成年人向特定或非特定群体推荐新冠疫苗接种意愿的因素
Healthcare (Basel). 2024 Jul 10;12(14):1377. doi: 10.3390/healthcare12141377.
5
Effectiveness of COVID-19 vaccines against severe COVID-19 among patients with cancer in Catalonia, Spain.西班牙加泰罗尼亚地区癌症患者感染 COVID-19 疫苗对重症 COVID-19 的有效性。
Nat Commun. 2024 Jun 19;15(1):5088. doi: 10.1038/s41467-024-49285-y.
6
Effectiveness of different booster vaccine combinations against SARS-CoV-2 during a six-month follow-up in Mexico and Argentina.墨西哥和阿根廷六个月随访期间不同加强疫苗组合对 SARS-CoV-2 的有效性。
Front Immunol. 2024 May 14;15:1403784. doi: 10.3389/fimmu.2024.1403784. eCollection 2024.
7
Immune response of COVID-19 vaccines in solid cancer patients: A meta-analysis.COVID-19 疫苗在实体瘤患者中的免疫应答：一项荟萃分析。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2357424. doi: 10.1080/21645515.2024.2357424. Epub 2024 May 24.
8
Immunogenicity of COVID-19 adsorbed inactivated vaccine (CoronaVac) and additional doses of mRNA BNT162b2 vaccine in immunocompromised adults compared with immunocompetent persons.与免疫功能正常者相比，新冠病毒吸附灭活疫苗（科兴疫苗）及额外剂量的mRNA BNT162b2疫苗在免疫功能低下成人中的免疫原性。
Rev Inst Med Trop Sao Paulo. 2024 Apr 19;66:e24. doi: 10.1590/S1678-9946202466024. eCollection 2024.
9
Boosting Vaccine Response in Autoimmune Rheumatic Disease Patients With Inadequate Seroconversion: An Analysis of the Immunogenicity of Vector-Based and Inactivated Vaccines.提高血清转化不足的自身免疫性风湿病患者的疫苗反应：基于载体和灭活疫苗免疫原性分析
Cureus. 2024 Mar 7;16(3):e55764. doi: 10.7759/cureus.55764. eCollection 2024 Mar.
10
Comparative Analysis of SARS-CoV-2 Antibody Responses across Global and Lesser-Studied Vaccines.全球及研究较少的新冠疫苗的SARS-CoV-2抗体反应对比分析
Vaccines (Basel). 2024 Mar 19;12(3):326. doi: 10.3390/vaccines12030326.
本文引用的文献
1
High seroconversion rates amongst black and Hispanics with hematologic malignancies after SARS-CoV-2 vaccination.SARS-CoV-2疫苗接种后，血液系统恶性肿瘤的黑人和西班牙裔人群血清转化率较高。
Leuk Lymphoma. 2022 Oct;63(10):2484-2488. doi: 10.1080/10428194.2022.2074988. Epub 2022 May 20.
2
Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study.BNT162b2 mRNA COVID-19 疫苗加强针在预防以色列重症结局的有效性：一项观察性研究。
Lancet. 2021 Dec 4;398(10316):2093-2100. doi: 10.1016/S0140-6736(21)02249-2. Epub 2021 Oct 29.
3
Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination setting.BNT162b2mRNA 新冠疫苗在全国大规模疫苗接种环境中对血液系统恶性肿瘤患者的有效性。
Blood. 2022 Mar 10;139(10):1439-1451. doi: 10.1182/blood.2021013768.
4
Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months.辉瑞-BioNTech 新冠疫苗接种 6 个月后免疫体液反应逐渐减弱。
N Engl J Med. 2021 Dec 9;385(24):e84. doi: 10.1056/NEJMoa2114583. Epub 2021 Oct 6.
5
Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies.B细胞源性血液系统恶性肿瘤患者对SARS-CoV-2加强疫苗接种的抗刺突抗体反应
Cancer Cell. 2021 Oct 11;39(10):1297-1299. doi: 10.1016/j.ccell.2021.09.001. Epub 2021 Sep 7.
6
Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients.移植受者中第三剂mRNA-1273疫苗的随机试验。
N Engl J Med. 2021 Sep 23;385(13):1244-1246. doi: 10.1056/NEJMc2111462. Epub 2021 Aug 11.
7
Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies.血液系统恶性肿瘤患者对SARS-CoV-2疫苗的抗体反应。
Cancer Cell. 2021 Aug 9;39(8):1031-1033. doi: 10.1016/j.ccell.2021.07.012. Epub 2021 Jul 22.
8
Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer.mRNA 疫苗在癌症患者中的免疫原性。
Cancer Cell. 2021 Aug 9;39(8):1091-1098.e2. doi: 10.1016/j.ccell.2021.06.009. Epub 2021 Jun 18.
9
Seroconversion rates following COVID-19 vaccination among patients with cancer.癌症患者接种 COVID-19 疫苗后的血清转化率。
Cancer Cell. 2021 Aug 9;39(8):1081-1090.e2. doi: 10.1016/j.ccell.2021.06.002. Epub 2021 Jun 5.
10
Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System.纽约医院系统中 COVID-19 癌症患者的病死率。
Cancer Discov. 2020 Jul;10(7):935-941. doi: 10.1158/2159-8290.CD-20-0516. Epub 2020 May 1.
Zotero 插件